Serodus ASA’s Board of Directors has in agreement with our CEO Eva Steiness decided to relieve her for the administrative burden to manage Serodus ASA from her permanent address in Denmark.

Serodus Board has appointed Mr. Arnstein Endresen, previous member of the Board of Directors and decided to place/outsource all SER150 management to the 100% Serodus ASA owned Danish subsidiary, Serodus ApS.

Eva Steiness is the CEO in Serodus ApS and will in this capacity continue to manage SER150 development for the treatment of patients with Diabetic Kidney Disease.